NEW YORK (Reuters) - Martin Shkreli, known for once hiking the price of a life-saving drug more than 4,000%, cannot return to the pharmaceutical industry after a federal appeals court on Tuesday upheld his lifetime ban.

A three-judge panel of the 2nd U.S. Circuit Court of Appeals in Manhattan said a lower court judge acted properly in imposing the ban and ordering Shkreli to repay $64.6 million because of his antitrust violations.

The case had been brought by the U.S. Federal Trade Commission (FTC), joined by New York, California, Illinois, North Carolina, Ohio, Pennsylvania and Virginia.

Shkreli, 40, became notorious and gained the sobriquet “Pharma Bro” when, as chief executive of Turing Pharmaceuticals in 2015, he raised the price of the newly-acquired antiparasitic drug Daraprim overnight to $750 per tablet from $17.50.

        • Hacksaw
          link
          fedilink
          arrow-up
          10
          arrow-down
          1
          ·
          10 months ago

          It’s not classism it’s capitalism. We’ve long accepted that people should die if they can’t pay, many people will even argue that it’s a good thing. Absolutely deranged system.

      • GoodEye8@lemm.ee
        link
        fedilink
        English
        arrow-up
        6
        ·
        10 months ago

        And guns don’t kill people. Once The bullet leaves the barrel it’s anyone’s guess where the bullet goes. If it happens to kill someone then the bullet was the issue, not the gun nor the person pulling the trigger.